Ming Xu

Dr. Ming Xu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2021 in La radiologia medica
Verified
Journal Article
Closed access
PDF file
DZDan Zeng
Dan Zeng
MXMing Xu
Ming Xu
JLJin-Yu Liang
Jin-Yu Liang
MCMei-Qing Cheng
Mei-Qing Cheng
HHHui Huang
Hui Huang
WWWei Wang
Wei Wang

7 April 2022 in European Radiology
Verified
Journal Article
Closed access
PDF file
JHJingzhi Huang
Jingzhi Huang
XXXiaohua Xie
Xiaohua Xie
HWHong Wu
Hong Wu
XZXiaoer Zhang
Xiaoer Zhang
YZYanling Zheng
Yanling Zheng
MXMing Xu
Ming Xu

26 December 2019 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
HGHuanling Guo
Huanling Guo
MXMing Xu
Ming Xu
ZCZhong Cao
Zhong Cao
WLWei Li
Wei Li
LCLi-Da Chen
Li-Da Chen
JLJie Liu
Jie Liu

21 September 2021 in Journal of Ultrasound in Medicine
Verified
Journal Article
Closed access
PDF file
MLMing-De Li
Ming-De Li
XLXiao-Zhou Lu
Xiao-Zhou Lu
JLJun-Feng Liu
Jun-Feng Liu
BCBin Chen
Bin Chen
MXMing Xu
Ming Xu
LCLi-Da Chen
Li-Da Chen

27 July 2024 in European Radiology
Verified
Journal Article
Closed access
PDF file
WXWenxin Xu
Wenxin Xu
HZHaoyan Zhang
Haoyan Zhang
RZRui Zhang
Rui Zhang
XZXian Zhong
Xian Zhong
XLXiaoju Li
Xiaoju Li
MXMing Xu
Ming Xu

1 August 2023 in Radiology
Verified
Journal Article
Closed access
XLXiaoju Li
Xiaoju Li
YZYutong Zhang
Yutong Zhang
XWXiaoli Wang
Xiaoli Wang
HZHua Zeng
Hua Zeng
LZLuyao Zhou
Luyao Zhou
MXMing Xu
Ming Xu
Background Infectious complications after percutaneous thermal ablation are seldom discussed, but better understanding of risk factors and early prediction is critical. Purpose To estimate the incidence of infectious complications after percutaneous thermal ablation of liver malignancies and to develop prediction models. Materials and Methods This single-center retrospective study reviewed the data of 3167 patients who underwent 7545 percutaneous US-guided thermal ablation procedures of liver malignancies between January 2010 and January 2022. All procedures with infectious complications were included as the case group. For each case, one treatment date-matched control subject without infection was randomly selected following a nested case-control design. Independent factors of overall and hepatobiliary infection were investigated with multivariable logistic regression. Results A total of 80 patients (median age, 59 years; IQR, 51-68 years; 64 men, 16 women) developed infectious complications after 80 ablation procedures; the incidence was 1.1% (80 of 7545 procedures). Of those with infection, 18% (14 of 80 patients) were severe, and 10% (eight of 80 patients) died as a result. Independent risk factors for overall infectious complication included prior biliary intervention (odds ratio [OR], 18.6; 95% CI: 4, 86; P < .001), prior transarterial chemoembolization (TACE) (OR, 2.4; 95% CI: 1.0, 5.8; P = .045), and the largest tumor size (OR, 1.9; 95% CI: 1.3, 2.8; P = .002); on this basis, subcapsular location was an additional risk factor of hepatobiliary infection. Prediction models for overall and hepatobiliary infection had an area under the receiver operating characteristics curve (AUC) of 0.77 and 0.82, respectively, both of which showed better AUC compared with the models, including prior biliary intervention alone (AUC = 0.63 and 0.65, respectively; P = .01 and P = .005, respectively). Conclusion Infectious complications after percutaneous thermal ablation of liver malignancies were uncommon but potentially fatal. Independent predictors were prior biliary intervention, prior transarterial chemoembolization, and the largest tumor size. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Ben-Arie and Sosna in this issue.